ONCOSIL MEDICAL LTD
ASX:OSLPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 58.9% of what they think they own, once every option and right converts.
Share count grew 288% in 24 months; runway 2–4 quarters; 3 cash raises in 24 months
ONCOSIL MEDICAL LTD underwent an approximately 1-for-400 share consolidation in May 2025. Between October 2024 and October 2026, its latest share-count filing, the adjusted ordinary share count rose 288% to 37M shares. The company raised capital three times in the 24-month window, with total disclosed proceeds of A$19.1M, most recently a A$5.6M placement in September 2026. Options and rights on issue could convert into 26M new shares, representing 69.9% of the current share count, of which none are in the money; the nearest expiry falls in April 2027. The company has 2 to 4 quarters of funding at the recent spend rate. No proposed securities issues are pending.
Quick answers · 3
When did OSL last raise capital?
The last capital raise in Oncosil Medical's filings is Placement of $5.6M announced 7 Sept 2026, one of 3 cash raises in 24 months.
How much cash does OSL have?
In its quarterly cash report for the quarter ended 30 June 2026, Oncosil Medical reported $6.5M of cash and estimated 2.5 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do OSL's options expire?
Unexercised options and rights equal 69.9% of Oncosil Medical's shares on issue; the nearest expiry is Apr 2027.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 26 Oct 2026 | 3H · cancellation | OSL : ORDINARY FULLY PAID | 36.7M | Appendix 3H |
| 15 Oct 2026 | 2A · quoted issue | OSL : ORDINARY FULLY PAID | 36.7M | Appendix 2A |
| 10 Sept 2026 | 2A · quoted issue | OSL : ORDINARY FULLY PAID | 34.9M | Appendix 2A |
| 10 Sept 2026 | 2A · quoted issue | OSL : ORDINARY FULLY PAID | 32.7M | Appendix 2A |
| 17 Aug 2026 | 2A · quoted issue | OSL : ORDINARY FULLY PAID | 30.9M | Appendix 2A |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
3 cash raises in the last 24 months · 2 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered25.4M · 69.2% of sharesOptions and warrants — they convert when the share price clears their exercise price.At least 24.3M of it states no exercise price — that much cannot be called in or out of the money.
- Condition-triggered229k · 0.6% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Exercise price on record: 407k priced, 687k at a stated nil price, 24.6M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
An exercise price is on record for only 1.6% of this supply, so what is in the money today is not a measurement — the tile above reads “—” for that reason. Of the priced supply, 0 is in the money at $0.71 today. No more priced supply until 3× today’s price, which takes it to 287k (0.8% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 687k (2.7% of the supply above) states a nil exercise price — nothing is paid to convert it, so no share price switches it on or off. It is the flat band, and it is not part of the in-the-money figure.
- 24.6M (95.7% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
- 120k more carries an exercise price above ten times today’s — off the right of this axis, and in every total on this page.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| OSLO | Options | Price-triggered, no exercise price stated | — | 30 Apr 2027 | 4.3M | Filing |
| OSLOE | Options | Price-triggered, no exercise price stated | — | 30 June 2027 | 10.3M | Filing |
| OSLOD | Options | Price-triggered, no exercise price stated | — | 31 July 2027 | 7.7M | Filing |
| OSLAN | Options | Price-triggered | $48.00 | 25 Oct 2027 | 10k | Filing |
| OSLOC | Options | Price-triggered, no exercise price stated | — | 20 Dec 2027 | 2.1M | Filing |
| OSLAT | Options | Price-triggered | $1.80 | 28 Nov 2028 | 114k | Filing |
| OSLAR | Options | Price-triggered | $12.00 | 29 Nov 2028 | 103k | Filing |
| OSLAC | Options | Price-triggered | Nil | 30 June 2029 | 687k | Filing |
| OSLAS | Options | Price-triggered | $12.00 | 14 Jan 2030 | 8k | Filing |
| OSLAU | Options | Price-triggered | $1.80 | 28 Nov 2030 | 173k | Filing |
| OSLAB | Performance rights | Condition-triggered | — | — | 229k | Filing Meeting |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 25 Oct 2026 | Nigel Lange | Sell incentive | — | — | 6k | — | 3Y notice |
| 17 Mar 2026 | Lelde Smits | Other placement | 44k | 44k | — | — | 3Y notice |
| 17 Mar 2026 | Nigel Lange | Other | 103k | 74k | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.